Page 358 - Programme book for The International Liver Congress 2015, EASL ILC 2015
P. 358
Late Breaker ePosters (Cont.)
LP29 A RANDOMISED PROSPECTIVE OPEN-LABEL TRIAL
COMPARING PEGINTERFERON + ADEFOVIR AND
PEGINTERFERON + TENOFOVIR VERSUS NO TREATMENT
IN HBEAG NEGATIVE CHRONIC HEPATITIS B PATIENTS
WITH LOW VIRAL LOAD: ANALYSIS OF WEEK 48 RESULTS
Annikki de Niet, Louis Jansen*, Femke Stelma, Sophie B. Willemse,
Sjoerd D. Kuiken, Sebastiaan Weijer, Karin M. van Nieuwkerk,
Hans L. Zaaijer, Richard Molenkamp, Robert B. Takkenberg,
Maarten Koot, Joanne Verheij, Ulrich Beuers, Hendrik W. Reesink,
The Netherlands
LP30 LIVER-DIRECTED ALLOSTERIC INHIBITORS OF
ACETYL-COA CARBOXYLASE FAVORABLY IMPACT
LATE BREAKER ePOSTERS PATHOPHYSIOLOGY IN THE PROGRESSION FROM
NAFLD TO NASH AND HEPATOCELLULAR CARCINOMA,
INCLUDING HEPATIC STEATOSIS, INFLAMMATION, AND
FIBROSIS
William F. Westlin*, H. J. Harwood, Danielle K. DePeralta,
Omeed Moaven, Lan Wei, Jeremy Greenwood, Sathesh Bhat,
Bryan C. Fuchs, Rosana Kapeller, Geraldine Harriman, The United States
LP31 STRENGTHENING VIRAL HEPATITIS SURVEILLANCE IN
EUROPE: RECOMMENDATIONS FROM TWO GLOBAL
HEPATITIS POLICY SURVEYS (2013 AND 2014)
Antons Mozalevskis*, Ida Sperle, Kelly Safreed-Harmon, Irina Eramova,
Martin C. Donoghoe, Jeffrey V. Lazarus, Denmark
LP32 REAL-WORLD EFFECTIVENESS OF LEDIPASVIR/
SOFOSBUVIR 8 WEEKS CHRONIC HEPATITIS C
TREATMENT
Peter Buggisch*, Joerg Petersen, Karsten Wursthorn, Petar Atanasov,
Aline Gauthier, Germany
LP33 EFFICACY OF INTERFERON+/- NUCLEOS(T)IDE ANALOG
TREATMENT IN CHILDREN WITH CHRONIC HEPATITIS B,
IN THE IMMUNOTOLERANT PHASE CONFIRMED BY LIVER
BIOPSY
Zhang Hongfei*, Zhu Shishu, Dong Yi, Wang Limin, Xu Zhiqiang,
Chen Dawei, Gan Yu, Wang Fuchuan, China
358 The International Liver Congress™ 2015 • ILC Programme
LP29 A RANDOMISED PROSPECTIVE OPEN-LABEL TRIAL
COMPARING PEGINTERFERON + ADEFOVIR AND
PEGINTERFERON + TENOFOVIR VERSUS NO TREATMENT
IN HBEAG NEGATIVE CHRONIC HEPATITIS B PATIENTS
WITH LOW VIRAL LOAD: ANALYSIS OF WEEK 48 RESULTS
Annikki de Niet, Louis Jansen*, Femke Stelma, Sophie B. Willemse,
Sjoerd D. Kuiken, Sebastiaan Weijer, Karin M. van Nieuwkerk,
Hans L. Zaaijer, Richard Molenkamp, Robert B. Takkenberg,
Maarten Koot, Joanne Verheij, Ulrich Beuers, Hendrik W. Reesink,
The Netherlands
LP30 LIVER-DIRECTED ALLOSTERIC INHIBITORS OF
ACETYL-COA CARBOXYLASE FAVORABLY IMPACT
LATE BREAKER ePOSTERS PATHOPHYSIOLOGY IN THE PROGRESSION FROM
NAFLD TO NASH AND HEPATOCELLULAR CARCINOMA,
INCLUDING HEPATIC STEATOSIS, INFLAMMATION, AND
FIBROSIS
William F. Westlin*, H. J. Harwood, Danielle K. DePeralta,
Omeed Moaven, Lan Wei, Jeremy Greenwood, Sathesh Bhat,
Bryan C. Fuchs, Rosana Kapeller, Geraldine Harriman, The United States
LP31 STRENGTHENING VIRAL HEPATITIS SURVEILLANCE IN
EUROPE: RECOMMENDATIONS FROM TWO GLOBAL
HEPATITIS POLICY SURVEYS (2013 AND 2014)
Antons Mozalevskis*, Ida Sperle, Kelly Safreed-Harmon, Irina Eramova,
Martin C. Donoghoe, Jeffrey V. Lazarus, Denmark
LP32 REAL-WORLD EFFECTIVENESS OF LEDIPASVIR/
SOFOSBUVIR 8 WEEKS CHRONIC HEPATITIS C
TREATMENT
Peter Buggisch*, Joerg Petersen, Karsten Wursthorn, Petar Atanasov,
Aline Gauthier, Germany
LP33 EFFICACY OF INTERFERON+/- NUCLEOS(T)IDE ANALOG
TREATMENT IN CHILDREN WITH CHRONIC HEPATITIS B,
IN THE IMMUNOTOLERANT PHASE CONFIRMED BY LIVER
BIOPSY
Zhang Hongfei*, Zhu Shishu, Dong Yi, Wang Limin, Xu Zhiqiang,
Chen Dawei, Gan Yu, Wang Fuchuan, China
358 The International Liver Congress™ 2015 • ILC Programme
